{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:52:23Z","timestamp":1787003543896,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1722906"],"award-info":[{"award-number":["1722906"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1722614"],"award-info":[{"award-number":["1722614"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1722665"],"award-info":[{"award-number":["1722665"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatitis C virus (HCV) is 15 times more prevalent among persons in Spain\u2019s prisons than in the community. Recently, Spain initiated a pilot program, JAILFREE-C, to treat HCV in prisons using direct-acting antivirals (DAAs). Our aim was to identify a cost-effective strategy to scale-up HCV treatment in all prisons. Using a validated agent-based model, we simulated the HCV landscape in Spain\u2019s prisons considering disease transmission, screening, treatment, and prison-community dynamics. Costs and disease outcomes under status quo were compared with strategies to scale-up treatment in prisons considering prioritization (HCV fibrosis stage vs. HCV prevalence of prisons), treatment capacity (2,000\/year vs. unlimited) and treatment initiation based on sentence lengths (&gt;6 months vs. any). Scaling-up treatment by treating all incarcerated persons irrespective of their sentence length provided maximum health benefits\u2013preventing 10,200 new cases of HCV, and 8,300 HCV-related deaths between 2019\u20132050; 90% deaths prevented would have occurred in the community. Compared with status quo, this strategy increased quality-adjusted life year (QALYs) by 69,700 and costs by \u20ac670 million, yielding an incremental cost-effectiveness ratio of \u20ac9,600\/QALY. Scaling-up HCV treatment with DAAs for the entire Spanish prison population, irrespective of sentence length, is cost-effective and would reduce HCV burden.<\/jats:p>","DOI":"10.1038\/s41598-019-52564-0","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T06:02:42Z","timestamp":1573711362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain\u2019s Prisons: A Cost-Effectiveness Study"],"prefix":"10.1038","volume":"9","author":[{"given":"Ozden O.","family":"Dalgic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeyye","family":"Samur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C.","family":"Spaulding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Llerena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turgay","family":"Ayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8741-4430","authenticated-orcid":false,"given":"Jagpreet","family":"Chhatwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"key":"52564_CR1","unstructured":"Prevalence of HIV and HCV infection in penitentiary institutions, http:\/\/www.institucionpenitenciaria.es\/web\/export\/sites\/default\/datos\/descargables\/saludpublica\/Prevalencia_VIH_y_VHC_en_IIPP_2016.pdf (2015)."},{"key":"52564_CR2","unstructured":"Susana Lierena, C. C. et al. A program of Testing and Treat Intended to Eliminate Hepatitis C in a Prison: The JAILFREE-C study. Abstract ID:916, AASLD Liver Meeting (2016)."},{"issue":"2","key":"52564_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"Jean-Michel Pawlotsky","year":"2018","unstructured":"EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 69, 461\u2013511, https:\/\/doi.org\/10.1016\/j.jhep.2018.03.026 (2018).","journal-title":"Journal of Hepatology"},{"key":"52564_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.7326\/M15-0617","volume":"164","author":"T He","year":"2016","unstructured":"He, T. et al. Prevention of hepatitis C by screening and treatment in US prisons. Annals of internal medicine 164, 84\u201392 (2016).","journal-title":"Annals of internal medicine"},{"key":"52564_CR5","doi-asserted-by":"publisher","first-page":"e003153","DOI":"10.1136\/bmjopen-2013-003153","volume":"3","author":"NK Martin","year":"2013","unstructured":"Martin, N. K. et al. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ open 3, e003153 (2013).","journal-title":"BMJ open"},{"key":"52564_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7326\/M14-0095","volume":"161","author":"M Kabiri","year":"2014","unstructured":"Kabiri, M., Jazwinski, A. B., Roberts, M. S., Schaefer, A. J. & Chhatwal, J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann. Intern. Med. 161, 170\u2013180 (2014).","journal-title":"Ann. Intern. Med."},{"key":"52564_CR7","first-page":"409A","volume":"66","author":"J Turnes","year":"2017","unstructured":"Turnes, J., Dominguez-Hernandez, R. & Casado, M. A. Health outcomes and costs associated with the implementation of a national treatment Plan for Hepatitis C in Spain. Hepatology 66, 409A\u2013409A (2017).","journal-title":"Hepatology"},{"key":"52564_CR8","first-page":"70","volume":"19","author":"J Crespo","year":"2018","unstructured":"Crespo, J., Llerena, S., Cobo, C. & Cabezas, J. Is HCV elimination possible in prison? Revista espanola de sanidad penitenciaria 19, 70\u201373 (2018).","journal-title":"Revista espanola de sanidad penitenciaria"},{"key":"52564_CR9","unstructured":"Chhatwal, J. et al. Projection of Patients who Fail Treatment in the Era of Direct-Acting Antivirals, Abstract #FRI-233. EASL 2017. 19\u201323 APRIL 2017, Amsterdam."},{"key":"52564_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/aje\/kwq422","volume":"173","author":"AC Spaulding","year":"2011","unstructured":"Spaulding, A. C. et al. Prisoner survival inside and outside of the institution: implications for health-care planning. American journal of epidemiology 173, 479\u2013487, https:\/\/doi.org\/10.1093\/aje\/kwq422 (2011).","journal-title":"American journal of epidemiology"},{"key":"52564_CR11","unstructured":"Plan estrat\u00e9gico para el abordaje de la Hepatitis C en el SNS (PEAHC), https:\/\/www.mscbs.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/hepatitisC\/PlanEstrategicoHEPATITISC\/docs\/Plan_Estrategico_Abordaje_Hepatitis_C_(PEAHC).pdf (2018)."},{"key":"52564_CR12","unstructured":"Indicadores sobre Gasto en productos farmac\u00e9uticos y sanitarios, http:\/\/www.hacienda.gob.es\/es-ES\/CDI\/Paginas\/EstabilidadPresupuestaria\/InformacionAAPPs\/Indicadores-sobre-Gasto-Farmac%C3%A9utico-y-Sanitario.aspx (2019)."},{"key":"52564_CR13","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Jurado, L. et al. Evaluaci\u00f3n econ\u00f3mica de la elastograf\u00eda de transici\u00f3n (FibroScan\u00ae) en el diagn\u00f3stico de fibrosis hep\u00e1tica en pacientes con hepatitis C coinfectados con VIH. 30, 294\u2013299 (2012).","DOI":"10.1016\/j.eimc.2011.11.004"},{"key":"52564_CR14","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/j.1572-0241.2003.07332.x","volume":"98","author":"CAKY Chong","year":"2003","unstructured":"Chong, C. A. K. Y. et al. Health-state utilities and quality of life in hepatitis C patients. The American journal of gastroenterology 98, 630\u2013638 (2003).","journal-title":"The American journal of gastroenterology"},{"key":"52564_CR15","unstructured":"Chhatwal, J., Kanwal, F., Roberts, M. & Dunn, M. Economic and clinical impact of sofosbuvir- and ledipasvir-based hepatitis C treatment in the United States. Ann Intern Med. In press (2015)."},{"key":"52564_CR16","unstructured":"Vallejo-Torres, L. et al. Valor Monetario de un A\u00f1o de Vida Ajustado por Calidad: Estimaci\u00f3n emp\u00edrica del coste de oportunidad en el Sistema Nacional de Salud (2015)."},{"key":"52564_CR17","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/S0213-9111(02)71933-X","volume":"16","author":"JA Sacristan","year":"2002","unstructured":"Sacristan, J. A., Oliva, J., Del Llano, J., Prieto, L. & Pinto, J. L. What is an efficient health technology in Spain? Gaceta sanitaria 16, 334\u2013343 (2002).","journal-title":"Gaceta sanitaria"},{"key":"52564_CR18","doi-asserted-by":"publisher","first-page":"546","DOI":"10.7326\/M14-0602","volume":"161","author":"S Liu","year":"2014","unstructured":"Liu, S., Watcha, D., Holodniy, M. & Goldhaber-Fiebert, J. D. J. Aoim Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in US incarcerated populations: a cost-effectiveness analysis. Annals of internal medicine 161, 546\u2013553 (2014).","journal-title":"Annals of internal medicine"},{"key":"52564_CR19","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/hep.28497","volume":"63","author":"NK Martin","year":"2016","unstructured":"Martin, N. K. et al. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology (Baltimore, Md.) 63, 1796\u20131808, https:\/\/doi.org\/10.1002\/hep.28497 (2016).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"52564_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/add.13783","author":"J Stone","year":"2017","unstructured":"Stone, J. et al. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction (Abingdon, England). https:\/\/doi.org\/10.1111\/add.13783 (2017).","journal-title":"Addiction (Abingdon, England)"},{"key":"52564_CR21","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/s41395-018-0157-x","volume":"113","author":"A Cuadrado","year":"2018","unstructured":"Cuadrado, A. et al. Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. The American journal of gastroenterology 113, 1639\u20131648, https:\/\/doi.org\/10.1038\/s41395-018-0157-x (2018).","journal-title":"The American journal of gastroenterology"},{"key":"52564_CR22","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1360-0443.2005.01050.x","volume":"100","author":"KA Dolan","year":"2005","unstructured":"Dolan, K. A. et al. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction 100, 820\u2013828 (2005).","journal-title":"Addiction"},{"key":"52564_CR23","unstructured":"National Institute of Statistics, http:\/\/www.ine.es\/ (2019)."},{"key":"52564_CR24","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","volume":"52","author":"AC Cardoso","year":"2010","unstructured":"Cardoso, A. C. et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. Journal of Hepatology 52, 652\u2013657 (2010).","journal-title":"Journal of Hepatology"},{"key":"52564_CR25","doi-asserted-by":"crossref","unstructured":"Cottrell, E. B., Chou, R., Wasson, N., Rahman, B. & Guise, J.-M. J. A. o. i. m. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the US Preventive Services Task Force. 158, 109\u2013113 (2013).","DOI":"10.7326\/0003-4819-158-2-201301150-00575"},{"key":"52564_CR26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s11524-007-9248-5","volume":"85","author":"JE Brady","year":"2008","unstructured":"Brady, J. E. et al. Estimating the prevalence of injection drug users in the US and in large US metropolitan areas from 1992 to 2002. J urban health 85, 323\u2013351 (2008).","journal-title":"J urban health"},{"key":"52564_CR27","doi-asserted-by":"crossref","unstructured":"Mumola, C. J. & Karberg, J. C. Drug use and dependence, state and federal prisoners, 2004. Bureau of Justice Statistics Special Report NCJ 213530 (2006).","DOI":"10.1037\/e560272006-001"},{"key":"52564_CR28","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt, L. et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. The Lancet Global Health 5, e1192\u2013e1207, https:\/\/doi.org\/10.1016\/S2214-109X(17)30375-3 (2017).","journal-title":"The Lancet Global Health"},{"key":"52564_CR29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/10826080701203013","volume":"43","author":"D Vlahov","year":"2008","unstructured":"Vlahov, D. et al. Mortality risk among recent-onset injection drug users in five US Cities. Subst Use Misuse 43, 413\u2013428 (2008).","journal-title":"Subst Use Misuse"},{"key":"52564_CR30","unstructured":"Crespo, J. et.al. Is elimination of HCV infection from penitentiary centers possible? The Jailfree-C trial: a sustained \u201ctest and treat\u201d program in inmates. Manuscript submitted to the Am J Gastroenterology."},{"key":"52564_CR31","unstructured":"Da Silva A et al. Variables asociadas a la discontinuaci\u00f3n del tratamiento en presos tratados de hepatitis C cr\u00f3nica en Catalu\u00f1a en el periodo 2002\u20132016. Qu\u00e9 ha cambiado con el uso de los antivirales de acci\u00f3n directa? GEHEP congress 2017, Poster 070."},{"key":"52564_CR32","unstructured":"Tellez, F. et al. Eficacia de la terapia con AAD en los centros penitenciarios de Puerto I, II y III.GEHEP congress 2017; Poster O42."},{"key":"52564_CR33","unstructured":"Daivozadeh, G. et al. An\u00e1lisis descriptivo de la situaci\u00f3n de la hepatitis C en los centros penitenciarios de Puerto I, II y III. GEHEP congress 2016; Oral 15."},{"key":"52564_CR34","unstructured":"Peinado, M. et al. Tratamiento directamente observado con antivirales de acci\u00f3n directa del virus de la Hepatitis C en pacientes del centro penitenciario de Valencia-Picassent. GEHEP congress 2016, Poster 62."},{"key":"52564_CR35","unstructured":"Marco, A. et al. An\u00e1lisis del uso de antivirales de acci\u00f3n directa en la pr\u00e1ctica cl\u00ednica para el tratamiento de la Hepatitis C Cr\u00f3nica en las prisiones de Catalu\u00f1a. GEHEP congress 2016; Poster 52."},{"key":"52564_CR36","unstructured":"Fernandez, F. et al. Sofosbuvir\/ledipasvir in Spanish prison population with chronic hepatitis C. EASL congress 2016; Poster SAT-154."},{"key":"52564_CR37","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/hep.22375","volume":"48","author":"HH Thein","year":"2008","unstructured":"Thein, H. H., Yi, Q., Dore, G. J. & Krahn, M. D. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 48, 418\u2013431, https:\/\/doi.org\/10.1002\/hep.22375 (2008).","journal-title":"Hepatology"},{"key":"52564_CR38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1053\/j.gastro.2008.09.014","volume":"136","author":"AS Lok","year":"2009","unstructured":"Lok, A. S. et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136, 138\u2013148, https:\/\/doi.org\/10.1053\/j.gastro.2008.09.014 (2009).","journal-title":"Gastroenterology"},{"key":"52564_CR39","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","volume":"112","author":"G Fattovich","year":"1997","unstructured":"Fattovich, G. et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112, 463\u2013472 (1997).","journal-title":"Gastroenterology"},{"key":"52564_CR40","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jhep.2004.01.005","volume":"40","author":"R Planas","year":"2004","unstructured":"Planas, R. et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. Journal of Hepatology 40, 823\u2013830 (2004).","journal-title":"Journal of Hepatology"},{"key":"52564_CR41","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","volume":"138","author":"G Davis","year":"2010","unstructured":"Davis, G., Alter, M., El-Serag, H., Poynard, T. & Jennings, L. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138, 513\u2013521 (2010).","journal-title":"Gastroenterology"},{"key":"52564_CR42","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/j.1600-6143.2010.03037.x","volume":"10","author":"P Thuluvath","year":"2010","unstructured":"Thuluvath, P. et al. Liver transplantation in the United States, 1999\u20132008. American Journal of Transplantation 10, 1003\u20131019 (2010).","journal-title":"American Journal of Transplantation"},{"key":"52564_CR43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jhep.2008.07.029","volume":"50","author":"K Lang","year":"2009","unstructured":"Lang, K., Danchenko, N., Gondek, K., Shah, S. & Thompson, D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 50, 89\u201399 (2009).","journal-title":"J Hepatol"},{"key":"52564_CR44","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/lt.21998","volume":"16","author":"S Saab","year":"2010","unstructured":"Saab, S., Hunt, D. R., Stone, M. A., McClune, A. & Tong, M. J. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: A decision analysis model. Liver Transpl 16, 748\u2013759 (2010).","journal-title":"Liver Transpl"},{"key":"52564_CR45","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/j.1600-6143.2010.03021.x","volume":"10","author":"R Wolfe","year":"2010","unstructured":"Wolfe, R., Roys, E. & Merion, R. Trends in organ donation and transplantation in the United States, 1999\u20132008. American Journal of Transplantation 10, 961\u2013972 (2010).","journal-title":"American Journal of Transplantation"},{"key":"52564_CR46","unstructured":"Centers for Medicare and Medicaid Services. Fee schedules, Available at: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/ClinicalLabFeeSched\/index.html?redirect=\/ClinicalLabFeesched (lab fees) and https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/PhysicianFeeSched\/index.html?redirect=\/PhysicianFeeSched (physician fees) (2019)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52564-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52564-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52564-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T11:02:42Z","timestamp":1671274962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52564-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["52564"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-52564-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,14]]},"assertion":[{"value":"6 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"<i>Spaulding<\/i> has accepted honoraria for speaking engagements from third-party entities funded by Abbvie, Gilead Sciences and Merck; no commercial entity had input on the content of the talks. <i>Crespo<\/i> has received consultancy and lecture fees from AbbVie, Celgene, Gilead Sciences, Intercept, Janssen and Merck Sharp & Dohme, Novartis. <i>Crespo<\/i> received grant support from AbbVie, Celgene, Intercept. <i>Ayer<\/i> has received consulting fee from Merck and Gilead. <i>Chhatwal<\/i> has received research grants and consulting fee from Gilead and Merck. All other authors have nothing to disclose in the past 12 months.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16849"}}